Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.
Journal Article (Journal Article)
Aim: To examine the prognostic value of the platelet-to-lymphocyte ratio (PLR) in the adjuvant renal cell carcinoma setting. Materials & methods: Patients received adjuvant sunitinib (50 mg/day; 4 weeks on/2 weeks off) or placebo. The primary end point was disease-free survival (DFS). Results: In 609 patients, DFS was similar for baseline PLR <140 versus ≥140 overall (median: 6.4 vs 5.9 years; hazard ratio: 0.9; 95% CI: 0.7-1.2). A ≥25% decrease in PLR at week 4 overall was associated with longer DFS versus no change (hazard ratio: 0.8; 95% CI: 0.6-1.0). Conclusion: Baseline PLR was not prognostic for DFS with adjuvant sunitinib treatment in patients with renal cell carcinoma. Clinical Trials Registration: NCT00375674 (ClinicalTrials.gov).
Full Text
Duke Authors
Cited Authors
- Patel, A; Ravaud, A; Motzer, RJ; Pantuck, AJ; Staehler, M; Escudier, B; Martini, J-F; Lechuga, M; Lin, X; George, DJ
Published Date
- February 2021
Published In
Volume / Issue
- 17 / 4
Start / End Page
- 403 - 409
PubMed ID
- 33028084
Pubmed Central ID
- PMC8488532
Electronic International Standard Serial Number (EISSN)
- 1744-8301
Digital Object Identifier (DOI)
- 10.2217/fon-2020-0652
Language
- eng
Conference Location
- England